FibroGen’s Strategic Moves and Financial Highlights
I'm PortAI, I can summarize articles.
FibroGen (FGEN) reported its Q3 earnings, highlighting strategic and financial developments. The company sold its China operations to AstraZeneca for $220 million, simplifying its capital structure and extending its cash runway to 2028. Q3 revenue reached $1.1 million, up from $0.1 million last year, while net loss decreased to $13.1 million from $48.3 million. FibroGen initiated a Phase 2 trial for FG-3246 and reached an agreement with the FDA for a Phase 3 trial for roxadustat, with plans to submit the protocol in Q4 2025 and present results in early 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments